These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Substituted ergolines: potential antipsychotics with unique profile. I. Psychopharmacological characterization. Groó D; Palosi A Pol J Pharmacol Pharm; 1988; 40(6):593-601. PubMed ID: 2908363 [TBL] [Abstract][Full Text] [Related]
48. Synthesis and Characterization of new Azecine-Derivatives as Potential Neuroleptics. Zergiebel S; Fleck C; Arndt HD; Enzensperger C; Seeling A Drug Res (Stuttg); 2017 Aug; 67(8):466-475. PubMed ID: 28521372 [TBL] [Abstract][Full Text] [Related]
49. 10-(Alkylamino)-4H-thieno[3,4-b][1,5]benzodiazepines. A novel class of potential neuroleptic agents. Press JB; Hofmann CM; Eudy NH; Fanshawe WJ; Day IP; Greenblatt EN; Safir SR J Med Chem; 1979 Jun; 22(6):725-31. PubMed ID: 37338 [TBL] [Abstract][Full Text] [Related]
51. Direct effect of neuroleptics on glutamate release. Sherman AD; Mott J Neuropharmacology; 1984 Nov; 23(11):1253-9. PubMed ID: 6084822 [TBL] [Abstract][Full Text] [Related]
52. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. Wadenberg ML; Hertel P; Fernholm R; Hygge Blakeman K; Ahlenius S; Svensson TH J Neural Transm (Vienna); 2000; 107(10):1229-38. PubMed ID: 11129112 [TBL] [Abstract][Full Text] [Related]
53. Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives with mixed 5HT1A/D2 affinity as potential atypical antipsychotics. Taverne T; Diouf O; Depreux P; Poupaert JH; Lesieur D; Guardiola-Lemaître B; Renard P; Rettori MC; Caignard DH; Pfeiffer B J Med Chem; 1998 Jun; 41(12):2010-8. PubMed ID: 9622542 [TBL] [Abstract][Full Text] [Related]
54. Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates - characterization by in vivo experiments. Schulze M; Siol O; Robaa D; Mueller FK; Enzensperger C; Fleck C; Lehmann J Arzneimittelforschung; 2012 May; 62(5):252-60. PubMed ID: 22488415 [TBL] [Abstract][Full Text] [Related]
55. Differential antagonism by neuroleptics of backward-walking and other behaviours caused by amphetamine at high dosage. Fernando JC; Lees AJ; Curzon G Neuropharmacology; 1980 Jun; 19(6):549-53. PubMed ID: 6105628 [No Abstract] [Full Text] [Related]
56. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Hadden MK; Orwig KS; Kokko KP; Mazella J; Dix TA Neuropharmacology; 2005 Dec; 49(8):1149-59. PubMed ID: 16095636 [TBL] [Abstract][Full Text] [Related]
57. The effect of butaclamol and of other neuroleptic agents on the apomorphine-elicited inhibition of synaptosomal tyrosine hydroxylase activity. Bronaugh RL; Tabak J; Ohashi T; Goldstein M Psychopharmacol Commun; 1975; 1(5):501-10. PubMed ID: 7003 [TBL] [Abstract][Full Text] [Related]
58. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain. Bissette G; Dauer WT; Kilts CD; O'Connor L; Nemeroff CB Neuropsychopharmacology; 1988 Dec; 1(4):329-35. PubMed ID: 2472151 [TBL] [Abstract][Full Text] [Related]
59. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418 [TBL] [Abstract][Full Text] [Related]
60. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2. van Wijngaarden I; Kruse CG; van der Heyden JA; Tulp MT J Med Chem; 1988 Oct; 31(10):1934-40. PubMed ID: 2902226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]